Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well vismodegib after stem cell transplant works in treating
patients with high-risk first remission or relapsed multiple myeloma. Vismodegib may slow the
growth of cancer cells. Giving vismodegib after autologous stem cell transplant may kill more
multiple myeloma cells.